Friday, December 19, 2014

AbbVie says newly approved hepatitis C treatment costs $83,319

(Reuters) - An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc. U.S. health regulators earlier on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead. (Reporting by Caroline Humer)



via Health News Headlines - Yahoo News http://ift.tt/1HcqDVe

No comments:

Post a Comment